|
ZNF295 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62525548574877E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62736490949555E-12 |
| Normal-vs-Stage2 |
1.63768998362457E-12 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
9.639800E-01 |
| Stage1-vs-Stage3 |
4.348100E-02 |
| Stage1-vs-Stage4 |
1.775850E-03 |
| Stage2-vs-Stage3 |
1.414830E-01 |
| Stage2-vs-Stage4 |
2.328300E-02 |
| Stage3-vs-Stage4 |
3.331800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.7715611723761E-16 |
| Normal-vs-AfricanAmerican |
2.07560000298201E-08 |
| Normal-vs-Asian |
<1E-12 |
| Caucasian-vs-AfricanAmerican |
3.207800E-01 |
| Caucasian-vs-Asian |
3.064200E-01 |
| AfricanAmerican-vs-Asian |
1.393180E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62636570877339E-12 |
| Male-vs-Female |
3.775600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.5527136788005E-15 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62470037423645E-12 |
| Normal-vs-Age(81-100Yrs) |
6.842200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.164000E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.673380E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.556000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.539600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.363400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.488000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.63970000000213E-05 |
| Classical-VS-Follicular |
4.739800E-01 |
| Classical-VS-Other |
1.935600E-02 |
| Classical-VS-Normal |
7.99360577730113E-15 |
| Tall-VS-Follicular |
7.86580000000647E-05 |
| Tall-VS-Other |
9.014000E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
1.010370E-02 |
| Follicular-VS-Normal |
4.88498130835069E-14 |
| Other-VS-Normal |
1.69797509386171E-12 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.33066907387547E-16 |
| Normal-vs-N1 |
1.62447832963153E-12 |
| N0-vs-N1 |
1.169780E-01 |
|
|
